On Friday, Cameron International Corporation (NYSE:CAM)’s shares declined -1.34% to $49.48.
Cameron (CAM) plans to hold a conference call on Thursday, October 22, 2015 at 9:30 a.m. eastern time to talk about its financial results for the third quarter of 2015. The company anticipates to issue a press release on its quarterly financial results the same day, before the U.S. markets open.
Cameron International Corporation provides flow equipment products, systems, and services worldwide. The companys Subsea segment offers integrated solutions, products, systems, and services to the subsea oil and gas market, counting integrated subsea production systems involving wellheads, subsea trees, manifolds and flowline connectors, and subsea processing systems. Its Surface segment provides onshore and offshore platform wellhead systems and processing solutions, counting valves, chokes, actuators, Christmas trees, and aftermarket services to oil and gas operators. This segment also offers rental equipment and artificial lift technologies; and products and services involving shale gas production.
Nektar Therapeutics (NASDAQ:NKTR)’s shares dropped -3.32% to $11.34.
Inogen, Inc. (INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, declared recently that R. Scott Greer has been designated as an independent director to its Board of Directors, effective August 3, 2015. In addition, Mr. Greer was designated to the Board’s Audit Committee. He will serve as a Class I director, with a term expiring at the annual meeting of stockholders to be held on October 14, 2015. Mr. Greer fills the vacancy created by the resignation of Timothy Petersen. Mr. Petersen had served as a member of Inogen’s Board since 2010.
Mr. Greer brings extensive executive and board level expertise to Inogen, in addition to a passion for the advancement of innovative healthcare technologies. He is presently a director of Sientra, Inc. (SIEN), in addition to numerous biopharmaceutical companies counting: Nektar Therapeutics (NKTR), StemCells, Inc. (STEM), and Versartis, Inc. (VSAR). Formerly, he was a director of Auspex Pharmaceuticals, Inc., Illumina, Inc., CV Therapeutics, Inc., Affymax, Inc., BAROnova, Inc., Chimeros, Inc., and Anaptys BioScience, Inc.
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline comprises drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology.
At the end of Friday’s trade, Pixeloperates, Inc. (NASDAQ:PXLW)‘s shares dipped -13.61% to $4.76.
Pixeloperates, Inc. (PXLW), an innovative provider of video display processing technology enabling the highest quality viewing experience for displays of all sizes, recently declared details of its formerly declared public offering of common stock. Pixeloperates has agreed to sell 3,250,000 shares of its common stock at a price of $4.75 per share, and has granted the underwriter an option to purchase up to 487,500 additional shares of common stock to cover over-allotments, if any. Subject to the satisfaction of customary conditions, the offering is predictable to close on or about August 12, 2015.
Pixeloperates, Inc. designs, develops, and markets video and pixel processing semiconductors, intellectual property cores, software, and custom ASIC solutions for digital video applications. Its products allow manufacturers and developers of digital display and projection devices to manufacture screens of various sizes that display the highest video quality with minimum power consumption.
TrueCar Inc (NASDAQ:TRUE), ended its Friday’s trading session with 3.97% gain, and closed at $5.76.
TrueCar, Inc. (TRUE), the negotiation-free car buying and selling platform, recently declared its financial results for the second quarter ended June 30, 2015.
Administration Transitions
TrueCar is also announcing that its Founder, Chief Executive Officer and Chairman, Scott Painter, will step down as CEO later this year. Mr. Painter will retire when his successor takes office, which is predictable to occur by year-end. Mr. Painter will continue to serve as Chairman of TrueCar’s Board of Directors.
Finally, TrueCar declared that Christopher Claus, former President of USAA Financial Advice & Solutions Group and a current director of TrueCar, has been named Lead Independent Director. Mr. Claus will focus on the Board’s search committee to find a new CEO in addition to building deeper ties with USAA.
TrueCar, Inc. operates as an Internet-based information, technology, and communication services company. The company operates its platform on the TrueCar Website and TrueCar mobile applications. It also customizes and operates its platform for its affinity group marketing partners, counting financial institutions, membership-based organizations, and employee buying programs for large enterprises.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
